Migraine Headaches Elimination With Patent Foramen Ovale-Directed Therapy
NCT07629635
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Migraine is a common and often disabling condition, but its exact causes are not fully understood. Some people with migraines have a small opening in the heart wall called a patent foramen ovale (PFO). In some of these patients, closing this opening or taking a medication that inhibits blood platelets (prasugrel) has been shown to reduce migraines. However, not everyone benefits, and it is unclear why. This study is being done to better understand whether closing a PFO can provide lasting migraine relief - especially in patients whose migraines improve with prasugrel.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Migraine Disease
- Patent Foramen Ovale
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Columbia University
- Last updated on ClinicalTrials.gov
- October 8, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 1
- Columbia University Irving Medical Center - NewYork Presbyterian Hospital (CUIMC/NYP) · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.